FierceBiotech9h
Deputy director of FDA’s CBER departs amid mass exodus at federal health agencies
Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER), ...
FierceBiotech15h
MeiraGTx gene therapy allows 11 blind children to see as biotech eyes accelerated approval
Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...
FierceBiotech15h
Procedural ‘loophole’ leaves NIH grants frozen, despite orders from federal judge: reports
The Trump administration is exploiting an administrative loophole to keep federal research funding frozen, despite a federal ...
FierceBiotech18h
Concentra curveball offer throws Acelyrin merger with Alumis into doubt
As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...
FierceBiotech17h
Chutes & Ladders—NIH leaders join health agency exodus
The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.
FierceBiotech13h
Roche rolls out new DNA 'sequencing-by-expansion' approach
Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of | Roche said ...
FierceBiotech19h
As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought
The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...